These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
473 related articles for article (PubMed ID: 23251575)
1. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575 [TBL] [Abstract][Full Text] [Related]
2. Assessing Homologous Recombination and Interstrand Cross-Link Repair in Embryonal Carcinoma Testicular Germ Cell Tumor Cell Lines. Cavallo F; Caggiano C; Jasin M; Barchi M Methods Mol Biol; 2021; 2195():113-123. PubMed ID: 32852761 [TBL] [Abstract][Full Text] [Related]
3. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044 [TBL] [Abstract][Full Text] [Related]
4. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399 [TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. Lobo J; Constâncio V; Guimarães-Teixeira C; Leite-Silva P; Miranda-Gonçalves V; Sequeira JP; Pistoni L; Guimarães R; Cantante M; Braga I; Maurício J; Looijenga LHJ; Henrique R; Jerónimo C Mol Oncol; 2021 Apr; 15(4):846-865. PubMed ID: 33513287 [TBL] [Abstract][Full Text] [Related]
6. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment. Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182 [TBL] [Abstract][Full Text] [Related]
7. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Postel-Vinay S; Bajrami I; Friboulet L; Elliott R; Fontebasso Y; Dorvault N; Olaussen KA; André F; Soria JC; Lord CJ; Ashworth A Oncogene; 2013 Nov; 32(47):5377-87. PubMed ID: 23934192 [TBL] [Abstract][Full Text] [Related]
8. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition. Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642 [TBL] [Abstract][Full Text] [Related]
9. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. Romano FJ; Rossetti S; Conteduca V; Schepisi G; Cavaliere C; Di Franco R; La Mantia E; Castaldo L; Nocerino F; Ametrano G; Cappuccio F; Malzone G; Montanari M; Vanacore D; Quagliariello V; Piscitelli R; Pepe MF; Berretta M; D'Aniello C; Perdonà S; Muto P; Botti G; Ciliberto G; Veneziani BM; De Falco F; Maiolino P; Caraglia M; Montella M; De Giorgi U; Facchini G Oncotarget; 2016 Dec; 7(51):85641-85649. PubMed ID: 27821802 [TBL] [Abstract][Full Text] [Related]
10. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211 [TBL] [Abstract][Full Text] [Related]
11. Detection of impaired homologous recombination repair in NSCLC cells and tissues. Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959 [TBL] [Abstract][Full Text] [Related]
13. Inhibiting the MCM8-9 complex selectively sensitizes cancer cells to cisplatin and olaparib. Morii I; Iwabuchi Y; Mori S; Suekuni M; Natsume T; Yoshida K; Sugimoto N; Kanemaki MT; Fujita M Cancer Sci; 2019 Mar; 110(3):1044-1053. PubMed ID: 30648820 [TBL] [Abstract][Full Text] [Related]
14. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912 [TBL] [Abstract][Full Text] [Related]
15. High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. Beyrouthy MJ; Garner KM; Hever MP; Freemantle SJ; Eastman A; Dmitrovsky E; Spinella MJ Cancer Res; 2009 Dec; 69(24):9360-6. PubMed ID: 19951990 [TBL] [Abstract][Full Text] [Related]
16. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726 [TBL] [Abstract][Full Text] [Related]
17. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine. Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464 [TBL] [Abstract][Full Text] [Related]
18. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272 [TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302 [TBL] [Abstract][Full Text] [Related]
20. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]